Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)
Year: 2005
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Institut Gustave Roussy, University of Chicago
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2305352133
